SB 1555: psilocybin services; regulation; licensure - Arizona

HOUSE - Amended by HHS - passed → Chaptered Version · 3 edits

MINOR

The bill was finalized and enacted into law as Chapter 231, removing committee markup and adding official chapter formatting. The substantive policy content regarding psilocybin regulation remains unchanged from the previous version.

Scope change

The bill's scope and applicability remain the same as the House version, with no substantive policy changes to the psilocybin regulation provisions.

TECHNICAL

Removed House committee markup and added official chapter formatting and legislative history headers.

Added official approval dates (Governor June 27, 2025) and Secretary of State filing information.

Replaced House amendment instructions with final enacted statute text.

Senate Engrossed Version → HOUSE - Amended by HHS - passed · 4 edits

MODERATE

The bill was amended by the House Health & Human Services Committee to add conditional enactment provisions that delay the law's effectiveness until psilocybin is federally approved and rescheduled by January 1, 2031. The amendment also adds legislative intent language emphasizing rapid patient access once federal approval occurs.

Scope change

The bill's applicability is now conditional on federal approval of psilocybin as a prescription medication and rescheduling under federal law, with a specific deadline of January 1, 2031.

TIMELINE

Added conditional enactment clauses requiring federal approval of crystalline polymorph psilocybin by January 1, 2031 before the law becomes effective.

REQUIREMENT

Added requirement for the Arizona State Board of Pharmacy to notify the legislative council of whether federal approval conditions were met by February 1, 2031.

DEFINITION

Added new section 36-2517.02 defining FDA-approved crystalline polymorph psilocybin as a controlled substance that may be prescribed in Arizona.

TECHNICAL

Added House committee header information and document metadata to the bill text.

House Engrossed Version → Senate Engrossed Version · 5 edits · Jun 19, 2025

MODERATE

This bill fundamentally transforms SB 1555 from a conditional psilocybin rescheduling measure into a comprehensive regulatory framework establishing a new Arizona Psilocybin Advisory Board. The House version focused on waiting for federal approval before allowing psilocybin prescriptions, while the Senate version creates an independent advisory body to oversee psilocybin services and research regardless of federal status.

Scope change

The bill's scope expanded from a conditional rescheduling of psilocybin to a full regulatory framework establishing a permanent advisory board with 12 members representing diverse stakeholders including healthcare providers, law enforcement, and mental health advocates.

REQUIREMENT

Established a new Arizona Psilocybin Advisory Board with 12 members appointed by the governor, senate president, and house speaker representing healthcare, law enforcement, mental health, and research communities.

Added requirement for the board to publish annual reports on psilocybin research, safety, efficacy, and comparative state policies by July 31, 2026.

Created new chapter 42 in Arizona Revised Statutes establishing the department of health services' role in psilocybin regulation.

TIMELINE

Removed conditional enactment provisions that would only allow psilocybin prescriptions after January 1, 2031, if federal approval and rescheduling occurred.

DEFINITION

Changed the bill title from focusing on 'approved medication' to 'psilocybin services' with broader regulatory and licensure provisions.

Introduced Version → House Engrossed Version · 6 edits · Jun 19, 2025

MODERATE

The bill was completely rewritten from a framework for regulating psychedelic-assisted therapy centers to a conditional authorization for prescribing FDA-approved crystalline polymorph psilocybin. The original version established a new advisory board, licensing requirements, and a control fund for psychedelic therapy centers, while the new version focuses on allowing prescription psilocybin only if the FDA approves and reschedules it by 2031.

Scope change

The bill's scope shifted from regulating private psychedelic therapy centers to creating a pathway for prescribing FDA-approved psilocybin medication, with strict conditions tied to federal approval.

SCOPE

Removed all provisions establishing a psychedelic-assisted therapy center licensing program, including definitions for centers, services, and indirect supervision.

FISCAL

Removed the establishment of a psilocybin control and regulation fund that would have collected fees and imposed civil penalties.

REQUIREMENT

Removed the Arizona Psilocybin Advisory Board and its 12-member appointment structure for oversight of therapy centers.

ELIGIBILITY

Added conditional provisions allowing prescription of crystalline polymorph psilocybin only if FDA approval and federal rescheduling occur by January 1, 2031.

TIMELINE

Added a 2031 deadline for federal approval, with the executive director required to notify the legislative council of whether conditions were met.

DEFINITION

Replaced therapy center definitions with nomenclature updates to include psilocybin in controlled substance schedules if federally approved.

psilocybin services; regulation; licensure

What changed between versions

How they voted

Actions timeline

Sponsors